Clinical Trial Update: Phase-II Trial of Induction Chemotherapy and Chemoradiotherapy Plus/Minus Durvalumab and Consolidation Immunotherapy in Patients With Resectable Stage III NSCLC. [Phase 2]

View source ↗

Summary

Phase II trial update exploring induction chemotherapy with chemoradiotherapy +/- durvalumab followed by consolidation immunotherapy in resectable Stage III non…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Durvalumab (durvalumab)

Snippet

Sponsor: University Hospital, Essen | Conditions: NSCLC, Stage III | Phase 2 | Status: UNKNOWN